Screen Shot 2020 01 13 at 9.25.21 AM

The Research Integration Venture (REINVENT) program is a collaborative research seed funding program for faculty projects within the Department of Anesthesiology and Perioperative Medicine.

The goal of REINVENT is to promote innovative research, encourage the integration of our clinical, basic, and translational research faculty, foster mentorship, and allocate resources (both time and money) transparently and competitively, with an eye toward future project sustainability. As a merit seed funding program, it encourages both intra-departmental and inter-departmental collaborations and team building, availability of academic time and financial support.

Collaboration is encouraged between clinical and basic/translational faculty; projects can focus on any aspect of research including clinical, education, quality, and operations.

For more information, click here to view the RFA or contact Brittany Massie at bmassie@uabmc.edu.

Awardees 

Fall Cycle

Andrew Barker, M.D.
The Effect of Guanfacine on Delirium in Elderly Critically Ill Patients 

Mark Powell, M.D.
Exosome cargo from preeclamptic patients mediates endothelial dysfuntion, subsequent cardiovascular remodeling, and the preeclamptic pehnotype

Alethia Selliers, M.D.
Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression

Rapid REINVENT

Due to the COVID-19 pandemic, our regular Spring REINVENT cycle was deferred and the Rapid REINVENT program was implemented in April. The purpose of the program was to promote and encourage innovation in COVID-19 research. Seven projects received funding in the first cycle in April and five projects received funding in May.

April Cycle 

Kevin S. Harrod, Ph.D. (PI), Brant Wagener, M.D., Ph.D. (Co-I), Jessy Deshane, Ph.D. (Co-I)
Modeling of COVID-19 and SARS-CoV-2 in human lung epithelium.

Qiang Ding, Ph.D., Kevin S. Harrod, Ph.D., Brant Wagener, M.D., Ph.D., Jean-Francois Pittet, M.D.
Repurposing already-available drugs to treat COVID-19; a pilot study for the effect of already-available drugs on COVID-19 virus entry and replication in lung epithelial and endothelial cells

Jean-Francois Pittet, M.D., DEAA and Jaroslaw W. Zmijewski, Ph.D.
Therapeutic recovery of immunosuppression and metabolic maladaptation induced by COVID-19 infection

Dylan R. Addis, M.D.
Investigation of VEGF and sFlt-1 levels in the pathogenesis and severity of COVID-19 disease

Zhen Zheng, M.D. M.S.
Penehyclidine protects lung from SARS-CoV-2-induced endothelial barrier disruption via limiting MLC2 phosphorylation - A novel intervention to ARDS in COVID-19

Brant Wagener, M.D. Ph.D., Timothy J. Ness, M.D. Ph.D., Sonya Heath, M.D., Sadis Matalon, Ph.D., D.Sc.
Exploratory study of the effect of tranexamic acid treatment on the progression of COVID-19 in Outpatients

Sadis Matalon, PhD, D.Sc. (PI), Ahmed Lazrak, D. Sc., (Co-PI)
Inhibition of Lung Ion Channel Activities by SARS CoV-2 S (spike) Protein

May Cycle

PI: Shama Ahmad, Ph.D., Co-PI: Aftab Ahmad, Ph.D.
Protease activated receptor (PAR) dependent cardiomyocyte damage due to SARS-CoV2 Spike protein

Co-PIs: Jean-Francois Pittet, M.D., Marisa Marques, M.D., Jori May, M.D. and Nita Limdi, Ph.D.
Insights into COVID-19-Mediated Activation of the Coagulation Cascade

PI: Saurabh Aggarwal, M.D., Ph.D.
The role of SARS-CoV-2 Spike Protein in Impairing Bactericidal Function of Macrophages: Therapeutic Potential of Raltegravir

PI: Jianguo Gu, M.B., Ph.D.; Co-PI: Sadis Matalon, Ph.D., Dr.Sc. (Hon.), FAPS
Neurogenic lung inflammation and its therapeutic implications in COVID-19

PI: Promil Kukreja, M.D.,Ph.D., Co-I: Hari Kalagara, M.D., Peter Nagi, M.D., Jeff Dobyns, M.D., MSHA
Effects of COVID pandemic on care and outcomes of elderly hip fracture patients.

Contact

McArdle Philip lowres

Mark Powell, M.D.
Resident researchers are available through the RMRET program. Please contact Dr. Powell for questions. 

 

Ayesha Bryant lowresAyesha Bryant, M.D., MSPH
IRB and regulatory assistance is available via Dr. Bryant. Applicants are encouraged to meet with Dr. Bryant prior to submitting their proposal to discuss the timeline required to obtain the necessary regulatory approval.